Evidence map›Paper›PMID 35140212›Full record

ArticleNature communications2022

Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance.

Paul F Lebeau, Jae Hyun Byun, Khrystyna Platko, Paul Saliba, Matthew Sguazzin, Melissa E MacDonald, Guillaume Paré, Gregory R Steinberg, Luke J Janssen, Suleiman A Igdoura and 5 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06359197 (Feasibility Study for Investigating the Effect of Caffeine Consumption on Protein Biomarkers Related to Cardiovascular Disease), which is not on this map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
21.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06359197 early_phase1unknown statusnot on this mapstarted 2024, after this paper: background citation

Feasibility Study for Investigating the Effect of Caffeine Consumption on Protein Biomarkers Related to Cardiovascular Disease

TypeinterventionalSponsorHamilton Health Sciences CorporationRan2024 to 2025Enrolled36ConditionsHealthyArmsCaffeine Pill, Placebo, TASSO+ Device, Finger prick and collection on Whatman Protein 903 Saver Cards, Intravenous Sampling
3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 108 citations in OpenAlex.

  1. Article
  2. Association of coffee consumption with diabetes mellitus and gestational diabetes mellitus.International journal of cardiology. Cardiovascular risk and prevention · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Experimental and therapeutic medicine · 2025
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 1 country.

Paul F Lebeau *Department of Medicine, Division of Nephrology, McMaster University, The Research Institute of St. Joe's Hamilton and the Hamilton Center for Kidney Research, Hamilton, ON, L8N 4A6, Canada.
Jae Hyun Byun *Department of Medicine, Division of Nephrology, McMaster University, The Research Institute of St. Joe's Hamilton and the Hamilton Center for Kidney Research, Hamilton, ON, L8N 4A6, Canada.
Khrystyna PlatkoDepartment of Medicine, Division of Nephrology, McMaster University, The Research Institute of St. Joe's Hamilton and the Hamilton Center for Kidney Research, Hamilton, ON, L8N 4A6, Canada.
Paul SalibaDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, L8S 4L8, Canada.ORCID http://orcid.org/0000-0001-6258-779X
Matthew SguazzinDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, L8S 4L8, Canada.
Melissa E MacDonaldDepartment of Medicine, Division of Nephrology, McMaster University, The Research Institute of St. Joe's Hamilton and the Hamilton Center for Kidney Research, Hamilton, ON, L8N 4A6, Canada.
Guillaume ParéPopulation Health Research Institute, McMaster University, Hamilton, ON, L8L 2X2, Canada.ORCID http://orcid.org/0000-0002-6795-4760
Gregory R SteinbergDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, L8S 4L8, Canada.ORCID http://orcid.org/0000-0001-5425-8275
Luke J JanssenFirestone Institute for Respiratory Health, St. Joseph's Hospital, Hamilton, ON, L8S 4K1, Canada.
Suleiman A IgdouraDepartment of Biology and Pathology, McMaster University, Hamilton, ON, L8S 4K1, Canada.
Mark A TarnopolskyDepartment of Medicine/Neurology, McMaster University, Hamilton, ON, L8N 3Z5, Canada.ORCID http://orcid.org/0000-0003-0312-3746
S R Wayne ChenLibin Cardiovascular Institute of Alberta, Department of Physiology and Pharmacology, University of Calgary, Calgary, AB, T2N 2T9, Canada.
Nabil G SeidahLaboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, affiliated to the University of Montreal, Montreal, QC, H2W 1R7, Canada.
Jakob MagolanDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, L8S 4L8, Canada.ORCID http://orcid.org/0000-0002-2947-8580
Richard C AustinDepartment of Medicine, Division of Nephrology, McMaster University, The Research Institute of St. Joe's Hamilton and the Hamilton Center for Kidney Research, Hamilton, ON, L8N 4A6, Canada. austinr@mcmaster.ca.ORCID http://orcid.org/0000-0003-0127-0865
McMaster University · CASt. Joseph’s Healthcare Hamilton · CAMcMaster University Medical Centre · CAMontreal Clinical Research Institute · CAPopulation Health Research Institute · CASt. Joseph's Hospital · CAThrombosis and Atherosclerosis Research Institute · CAUniversity of Calgary · CA

Funding

CIHR 148363CIHR FRN173520
6 · The paper itself

Abstract

Evidence suggests that caffeine (CF) reduces cardiovascular disease (CVD) risk. However, the mechanism by which this occurs has not yet been uncovered. Here, we investigated the effect of CF on the expression of two bona fide regulators of circulating low-density lipoprotein cholesterol (LDLc) levels; the proprotein convertase subtilisin/kexin type 9 (PCSK9) and the low-density lipoprotein receptor (LDLR). Following the observation that CF reduced circulating PCSK9 levels and increased hepatic LDLR expression, additional CF-derived analogs with increased potency for PCSK9 inhibition compared to CF itself were developed. The PCSK9-lowering effect of CF was subsequently confirmed in a cohort of healthy volunteers. Mechanistically, we demonstrate that CF increases hepatic endoplasmic reticulum (ER) Ca

Indexed as

AnimalsCaffeineCholesterolCholesterol, LDLHepatocytesHep G2 CellsHumansLipid MetabolismLiverMaleMiceMice, Inbred C57BLProprotein Convertase 9Receptors, LDLSterol Regulatory Element Binding Protein 2CaffeineCholesterolCholesterol, LDLLDLR protein, humanPCSK9 protein, humanProprotein Convertase 9Receptors, LDLSterol Regulatory Element Binding Protein 2

Identifiers

PMID35140212
PMCPMC8828868
OpenAlexW4210840666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.